Table 2.
Association of different levels of microRNA-15b with DR risk, stratified by disease stage
| Levels of microRNA-15b | NPDR | PDR | ||||||
|---|---|---|---|---|---|---|---|---|
| ORa | 95% CI | ORb | 95% CI | ORa | 95% CI | ORb | 95% CI | |
| 1 st quartile | 1 | reference | 1 | reference | 1 | reference | 1 | reference |
| 2 nd quartile | 0.26 | (0.09-0.76) | 0.20 | (0.06-0.68) | 0.63 | (0.27-1.46) | 0.45 | (0.16-1.25) |
| 3 rd quartile | 0.47 | (0.18-1.19) | 0.49 | (0.16-1.46) | 0.31 | (0.12-0.77) | 0.28 | (0.09-0.82) |
| 4 th quartile | 0.09 | (0.03-0.28) | 0.06 | (0.02-0.23) | 0.24 | (0.10-0.59) | 0.16 | (0.06-0.48) |
| For each 2-fold increase | 0.58 | (0.43-0.78) | 0.54 | (0.39-0.76) | 0.64 | (0.49-0.83) | 0.58 | (0.43-0.79) |
Abbreviations: Apoa, apolipoprotein A; Apob, apolipoprotein B; CI, confidence interval; HbA1c, hemoglobin A1c; NPDR, nonproliferative diabetic retinopathy; OR, odds ratio; PDR, proliferative diabetic neuropathy; RNA, ribonucleic acid; SBP, systolic blood pressure.
a Adjusted for age and sex.
b Adjusted for age, sex, oral drug, diabetes duration, hypertension duration, SBP, Apoa, Apob, and HbA1c.